Literature DB >> 17171401

Clinical study of therapeutic angiogenesis by autologous peripheral blood stem cell (PBSC) transplantation in 92 patients with critically ischemic limbs.

Akio Kawamura1, Takashi Horie, Ichiro Tsuda, Yoshihiro Abe, Masahiro Yamada, Hidetoshi Egawa, Jun-ichi Iida, Hiromi Sakata, Kazuhiko Onodera, Tohru Tamaki, Hidenori Furui, Kazutaka Kukita, Jun-ichi Meguro, Motoki Yonekawa, Shinya Tanaka.   

Abstract

Patients with critically ischemic limbs due to maintenance hemodialysis and diabetes are increasing in number markedly in Japan. The difficulty of treating critically ischemic limbs is well recognized. Despite active medication and surgical therapy, many critically ischemic limbs are amputated. Ninety-two patients with critically ischemic limbs were treated by transplantation of autologous peripheral blood stem cells (PBSCs). The stem cells were mobilized into the peripheral blood by administration of granulocyte colony stimulating factor (G-CSF). The mobilized mononuclear cells were separated by an apheresis technique using a centrifuge. The separated mononuclear cells contained approximately 4.0 x 10(7) CD34-positive cells. The collected cell suspension was divided into aliquots of 0.5-1.0 ml and transplanted into the muscle of ischemic limbs at 50-70 transplantation points. At 1.5 months after PBSC transplantation, a strong immunostaining of CD34-positive cells and factor VIII, as well as capillary formation, was observed in the muscles into which stems cells had been transplanted. In each patient tested, the serum vascular endothelial growth factor (VEGF) level increased after stem cell transplantation; the mean VEGF level increased by 176%. Of 11 diabetic patients (DM) who were not receiving hemodialysis (HD), there were no amputees regardless of their Fontaine classification. Of 19 patients in the HD(+)DM(-) category, there were no amputations in Fontaine stage I, II, and III patients, whereas three limbs and one toe were amputated in Fontaine stage IV patients. Of 13 patients in the HD(-)DM(+) category, none of the Fontaine stage I, II, or III patients underwent amputation, but six Fontaine stage IV patients underwent amputation. Of 49 patients in the HD(+)DM(+) category, 38 (78%) were classified as Fontaine stage IV, 71% (27/38) of whom had a toe or a limb amputated. In nine patients over 80 years of age, one toe and one limb were amputated. Nondiabetic, nondialyzed patients with ischemic limbs are strongly indicated for stem cell transplantation regardless of Fontaine classification. Therapeutic angiogenesis is effective for critically ischemic limbs resulting from hemodialysis and diabetes until Fontaine stage III, but is of limited effectiveness for stage IV cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17171401     DOI: 10.1007/s10047-006-0351-2

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  6 in total

1.  Peripheral vascular disease risk factors among patients undergoing hemodialysis.

Authors:  Ann M O'Hare; Chi-Yuan Hsu; Peter Bacchetti; Kirsten L Johansen
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

2.  Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis?

Authors:  Shoichi Inaba; Kensuke Egashira; Kimihiro Komori
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

3.  [Surgical treatment of peripheral circulation disorders].

Authors:  R FONTAINE; M KIM; R KIENY
Journal:  Helv Chir Acta       Date:  1954-12

4.  Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation.

Authors:  Akio Kawamura; Takashi Horie; Ichirou Tsuda; Atushi Ikeda; Hirotoshi Egawa; Emi Imamura; Jun-Ichi Iida; Hiromi Sakata; Tohru Tamaki; Kazutaka Kukita; Jun-ichi Meguro; Motoki Yonekawa; Masaharu Kasai
Journal:  Ther Apher Dial       Date:  2005-02       Impact factor: 1.762

5.  Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.

Authors:  Eriko Tateishi-Yuyama; Hiroaki Matsubara; Toyoaki Murohara; Uichi Ikeda; Satoshi Shintani; Hiroya Masaki; Katsuya Amano; Yuji Kishimoto; Kohji Yoshimoto; Hidetoshi Akashi; Kazuyuki Shimada; Toshiji Iwasaka; Tsutomu Imaizumi
Journal:  Lancet       Date:  2002-08-10       Impact factor: 79.321

6.  An overview of regular dialysis treatment in Japan (as of 31 December 2001).

Authors:  Shigeru Nakai; Takahiro Shinzato; Yuji Nagura; Ikuto Masakane; Tateki Kitaoka; Toshio Shinoda; Chikao Yamazaki; Rumi Sakai; Hiroyuki Ohmori; Osamu Morita; Kunitoshi Iseki; Kenjiro Kikuchi; Kazuo Kubo; Kazuyuki Suzuki; Kaoru Tabei; Kiyohide Fushimi; Naoko Miwa; Atsushi Wada; Mitsuru Yanai; Takashi Akiba
Journal:  Ther Apher Dial       Date:  2004-02       Impact factor: 1.762

  6 in total
  29 in total

1.  Journal of Artificial Organs 2006: the year in review.

Authors:  Y Sawa; T Horiuchi; A Kishida; T Masuzawa; M Nishimura; E Tatsumi; Y Tomizawa; H Watanabe
Journal:  J Artif Organs       Date:  2007-06-20       Impact factor: 1.731

Review 2.  Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand.

Authors:  Louis M Pelus
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

Review 3.  Clinical application of stem cells for therapeutic angiogenesis in patients with peripheral arterial disease.

Authors:  Kyung-Bok Lee; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

4.  Thromoboagiitis Obliterans (TAO).

Authors:  Ui-Jun Park; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

5.  Ex vivo activation of angiogenic property in human peripheral blood-derived monocytes by thrombopoietin.

Authors:  Toru Kawamoto; Junpei Sasajima; Yoshiaki Sugiyama; Kazumasa Nakamura; Hiroki Tanabe; Mikihiro Fujiya; Toshie Nata; Yasuyuki Iuchi; Toshifumi Ashida; Yoshihiro Torimoto; Yusuke Mizukami; Yutaka Kohgo
Journal:  Int J Hematol       Date:  2013-09-04       Impact factor: 2.490

6.  Transient extremity ischemia augments CD34+ progenitor cell availability.

Authors:  David Czeiger; Oleg Dukhno; Amos Douvdevani; Yael Porat; Daphna Shimoni; Valentin Fulga; Jared D Ament; Gad Shaked
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

7.  Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.

Authors:  S Fadilah Abdul Wahid; Nor Azimah Ismail; Wan Fariza Wan Jamaludin; Nor Asiah Muhamad; Muhammad Khairul Azaham Abdul Hamid; Hanafiah Harunarashid; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2018-08-29

8.  Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia.

Authors:  R K Burt; A Testori; Y Oyama; H E Rodriguez; K Yaung; M Villa; J M Bucha; F Milanetti; J Sheehan; N Rajamannan; W H Pearce
Journal:  Bone Marrow Transplant       Date:  2009-05-18       Impact factor: 5.483

Review 9.  Clinical Application of Endothelial Progenitor Cell: Are We Ready?

Authors:  Chao-Hung Wang; Po-Hsun Huang; Jaw-Wen Chen; Shing-Jong Lin; Ming-Feng Lee; Ning-I Yang; Wen-Jin Cherng
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

10.  Limited value of digital subtraction angiography in the evaluation of cell-based therapy in patients with limb ischemia.

Authors:  Robert B van Tongeren; Jaap F Hamming; Saskia le Cessie; Arian R van Erkel; J Hajo van Bockel
Journal:  Int J Cardiovasc Imaging       Date:  2009-09-16       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.